Argenica Therapeutics Finalizes FDA Safety Tests and Advances Plans for Late-Stage Stroke Clinical Trial

Completion of FDA Safety Assays Addresses Clinical Hold

During the June 2026 quarter, Argenica Therapeutics completed three critical safety assays requested by the US FDA to resolve a clinical hold on xaranetide. The hERG assay evaluated cardiac safety, the TNK assay assessed interactions with the clot-busting drug tenecteplase, and the genotox assay tested genotoxicity using an in vitro mammalian cell gene mutation assay. All assays returned favourable safety profiles, marking a significant de-risking milestone for the development program.

With the trial protocol nearing finalisation, Argenica is positioned to submit a detailed response to the FDA clinical hold and seek Investigational New Drug application approval. This regulatory clearance is crucial for initiating a late-stage clinical trial in acute ischaemic stroke patients in the US and removes a key obstacle to advancing the company’s US clinical development strategy.

WHO Confirms Xaranetide as Official International Generic Name

The World Health Organisation confirmed xaranetide as the International Nonproprietary Name (INN) for ARG-007 during the quarter, with no objections noted. Pronounced "za-RAN-e-tide," this designation formally recognises the drug’s generic name globally across regulatory, scientific, and medical fields, supporting its path toward commercialisation.

Argenica will now adopt xaranetide in all future communications, replacing the internal ARG-007 code. This change aligns the company with international pharmaceutical naming standards and facilitates clearer communication with healthcare professionals, regulators, and investors. The INN status strengthens the drug candidate’s recognition within the global medical and scientific communities as clinical development progresses.

Global Stroke Clinical Advisory Committee Shapes Late-Stage Trial Design

Argenica has established a global stroke Clinical Advisory Committee composed of international experts to refine the design of the upcoming late-stage clinical trial targeting moderate to severe acute ischaemic stroke patients. This effort builds on positive Phase 2 trial data collected across Australian hospitals in 2025, which demonstrated safety, efficacy, and an efficacy signal in severe stroke cases, supported by AI analyses from Brainomix.

The late-stage trial is being designed as either a Phase 2b or seamless Phase 2b/3 study, focusing on patient selection by stroke severity and employing AI-driven diagnostics to identify patients most likely to benefit. This precision medicine approach aims to improve clinical success rates and program efficiency. The trial design and strategy will be presented publicly in Q3 2026, with a protocol synopsis submitted to the FDA before the quarter’s end.

Manufacturing Scale-Up Progresses with Corden Pharma Partnership

Argenica is advancing drug substance manufacturing in collaboration with Corden Pharma (Europe), developing scaled production processes for xaranetide to support clinical trials and future commercial supply. This manufacturing progress is a vital step in de-risking the program and ensuring readiness for late-stage trial demands.

Partnering with an established contract manufacturing organisation like Corden Pharma enhances Argenica’s capacity to produce sufficient drug volumes for larger clinical trials and potential commercialisation. Manufacturing readiness is essential for regulatory approval to commence late-stage trials, confirming the company’s practical preparedness for this transition.

Preclinical Concussion Study Highlights Neuroprotective Benefits

Following the June 2026 quarter, Argenica reported preclinical concussion study results showing xaranetide significantly reduced secondary injury effects in a repeated mild traumatic brain injury model. These findings add to growing evidence of the drug’s neuroprotective potential across mild, moderate, and severe brain injury models, broadening its possible clinical applications beyond acute ischaemic stroke.

The company is evaluating next steps to advance xaranetide’s development for traumatic brain injury, a condition with substantial global health impact and limited effective treatments. While no timelines or clinical plans have been disclosed, these results complement Phase 2 stroke data and support the drug’s neuroprotective mechanism.

Robust Cash Position and Government Grants Support Development

As of 30 June 2026, Argenica held $6.35 million in cash reserves, enabling continued advancement of late-stage stroke trial preparations. The company is well-funded to support protocol development and regulatory interactions with the FDA, reflecting disciplined capital management and successful acquisition of non-dilutive funding.

In June 2025, Argenica secured up to $1.5 million in non-dilutive funding from the Australian Government’s Medical Research Future Fund Targeted Translation Research Accelerator program, supporting late-stage trial establishment. Additionally, over $4 million in grants and philanthropic funding has been obtained from federal and Western Australian governments, the Stan Perron Charitable Foundation, the McCusker Foundation, and Perron Institute donors. This blend of equity and non-dilutive funding offers financial flexibility without immediate shareholder dilution.

Ongoing Scientific and Clinical Outreach at International Events

Argenica continues to build clinical and scientific engagement for xaranetide through presentations at major global conferences. Two abstracts from the Phase 2 trial were presented at the European Stroke Organisation Conference, sharing safety and efficacy data with the international stroke research community. The company also participated in BIO 2026 in San Diego, a premier biotech industry event in North America.

These engagements enhance awareness and credibility for xaranetide among medical professionals and potential pharmaceutical partners, supporting late-stage trial collaborations. The European Stroke Organisation presentation validates Phase 2 findings independently, while BIO 2026 attendance fosters industry networking and commercial opportunities.

Regulatory Milestones and Timeline Through Q3 2026

Argenica has outlined a clear regulatory roadmap with key milestones through Q3 2026. The company plans to finalise the late-stage trial protocol shortly after consultations with the global Clinical Advisory Committee. Subsequently, a protocol synopsis will be submitted to the FDA for feedback, a critical step to align trial design with US regulatory standards, expected before the end of Q3 2026.

Successful completion of these steps will enable Argenica to respond comprehensively to the FDA clinical hold and seek Investigational New Drug application approval for xaranetide, permitting the initiation of the late-stage US clinical trial. This timeline offers investors transparency on near-term regulatory progress and late-stage development prospects. The Q3 2026 market presentation will provide detailed insights into the company’s clinical strategy and anticipated success probabilities.

Argenica’s Position in Neuroprotective Stroke Treatment Development

Headquartered in Perth, Western Australia, Argenica Therapeutics develops novel neuroprotective therapies aimed at reducing brain tissue death following acute ischaemic stroke and other brain injuries. The lead candidate, xaranetide, is primarily focused on acute ischaemic stroke, supported by preclinical data in traumatic brain injury models. Stroke remains a leading cause of death and disability worldwide, with limited effective pharmacological treatments beyond thrombolysis and thrombectomy.

Argenica’s approach targets neuroprotection to mitigate secondary brain injury occurring hours after stroke onset, complementing existing acute treatments. The development strategy incorporates precision medicine and AI-enabled diagnostics to optimize patient selection in late-stage trials, reflecting modern clinical trial design advances. Combined with positive Phase 2 data and completed FDA safety assays, the company has made substantial progress toward late-stage development and potential clinical validation of xaranetide’s neuroprotective mechanism.